GPCRMID

Structure Therapeutics Inc.

HealthcareBiotechnology
$40.84
$0.00(-0.63%)
52W$15.80
$94.90
Updated May 7, 12:00 AM
RSI31
RS Rating72/99
Beta0.96
Volatility61%
F-Score3/9
Mkt Cap$2.4B
CONSOLIDATING

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

CONSOLIDATING

Structure Therapeutics Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 72), indicating performance broadly in line with the market. Earnings growth of 195% provides fundamental context to the price action. Investors should exercise caution due to high volatility (61% annualized), which requires wider risk management.

Relative Strength
72
out of 99
Average
Trend Score
2/4
Minervini Criteria
CONSOLIDATING
Risk (Beta)
0.96
vs S&P 500
MARKET
52W Position
32%
from 52W low
Lower Half
Trend & Momentum Analysis

Trend Template (Minervini)

CONSOLIDATING2/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$51.72
50 SMA > 100 SMA$63.12
100 SMA > 150 SMA$53.33
150 SMA > 200 SMA$45.02

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$47.43-13.89%BELOW
50 SMA$51.72-21.04%BELOW
100 SMA$63.12-35.30%BELOW
150 SMA$53.33-23.42%BELOW
200 SMA$45.02-9.28%BELOW

Price Performance

1D-0.6%
1W-1.3%
1M-21.1%
3M-45.5%
6M+22.0%
YTD-40.0%
1Y+61.2%
3Y+19.4%
52-Week Trading Range32% from low
$40.84
52W Low$15.80
52W High$94.90

Technical Indicators

RSI (14)BEARISH
30.7
305070
VCP ScoreCOOL
3/10
Base depth: 99.2%

Risk Profile

Beta
0.96
52W Vol
61%
ATR
$2.78
Max DD (1Y)
-56%

Volume Analysis

Today
838.9K
50D Avg
946.7K
Vol Ratio
0.89x
Liquidity
MODERATE

Earnings Momentum

Q1'25-42%
$-0.81
Q2'25-100%
$-1.08
Q3'25-85%
$-1.11
Q4'25+195%
$0.60
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:
5 Years:
3 Years:
TTM:

Compounded Profit Growth

10 Years:
5 Years:
3 Years:
TTM:-2.56%

Stock Price CAGR

10 Years:+4.62%
5 Years:+9.45%
3 Years:+19.39%
1 Year:+61.23%

Return on Equity

10Y Avg:-27.8%
5Y Avg:-27.8%
3Y Avg:-27.8%
Last Year:-14.5%

Key Metrics

Market Cap$2.4B
Gross Margin
Net Margin
Piotroski F-Score3/9

Frequently Asked Questions

Is GPCR in an uptrend right now?

GPCR has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.

Is GPCR overbought or oversold?

GPCR's RSI (14) is 31. The stock is in neutral territory, neither overbought nor oversold.

Is GPCR outperforming the market?

GPCR has a Relative Strength (RS) Rating of 72 out of 99. GPCR is performing about average compared to the market.

Where is GPCR in its 52-week range?

GPCR is trading at $40.84, which is 43% of its 52-week high ($94.90) and 32% above its 52-week low ($15.80).

How volatile is GPCR?

GPCR has a Beta of 0.96 and 52-week volatility of 61%. It's less volatile than the S&P 500 - generally more stable.

Disclaimer: Data is for informational purposes only. May be delayed or contain errors. Past performance does not guarantee future results. This is not financial advice. Always conduct your own research and consult professionals before making investment decisions.